• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

替代搜索方法在检索健康经济建模效用值中的实证检验。

Empirical Testing of Alternative Search Methods to Retrieve Utility Values for Health Economic Modelling.

机构信息

University of Sheffield, SCHARR, 30 Regent Street, Sheffield, S1 4DA, UK.

Lumanity Limited, Sheffield, UK.

出版信息

Pharmacoeconomics. 2024 Nov;42(11):1255-1266. doi: 10.1007/s40273-024-01414-7. Epub 2024 Aug 6.

DOI:10.1007/s40273-024-01414-7
PMID:39107622
Abstract

OBJECTIVES

The objective of this study is to compare different information retrieval methods that can be used to identify utility inputs for health economic models.

METHODS

The usual practice of using systematic review methods was compared with two alternatives (iterative searching and rapid review), using a health technology assessment (HTA) case study in ulcerative colitis (UC). We analysed whether there were differences in the utility values identified when using the alternative search methods. Success was evaluated in terms of time, burden and relevance of identified information. The identified utility values were tested in an executable health economic model developed for UC, and the model results were compared.

RESULTS

The usual practice of using systematic review search approaches identified the most publications but was also the least precise method and took longest to complete. The inclusion of data from the different search methods in the model did not lead to different conclusions across search methods.

CONCLUSIONS

In this case study, usual practice was less efficient and resulted in the same health economic model conclusions as the alternative search methods. Further case studies are required to examine whether this conclusion might be generalisable.

摘要

目的

本研究旨在比较可用于识别卫生经济模型效用输入的不同信息检索方法。

方法

使用系统评价方法的常规实践与两种替代方法(迭代搜索和快速审查)进行了比较,使用溃疡性结肠炎(UC)的卫生技术评估(HTA)案例研究。我们分析了当使用替代搜索方法时,在识别效用值方面是否存在差异。成功与否取决于所确定信息的时间、负担和相关性。在为 UC 开发的可执行卫生经济模型中测试了所确定的效用值,并比较了模型结果。

结果

使用系统评价搜索方法的常规实践虽然识别出了最多的出版物,但也是最不精确的方法,且完成时间最长。将不同搜索方法的数据纳入模型并没有导致不同的搜索方法之间的结论不同。

结论

在本案例研究中,常规实践效率较低,与替代搜索方法得出的卫生经济模型结论相同。需要进一步的案例研究来检验这一结论是否具有普遍性。

相似文献

1
Empirical Testing of Alternative Search Methods to Retrieve Utility Values for Health Economic Modelling.替代搜索方法在检索健康经济建模效用值中的实证检验。
Pharmacoeconomics. 2024 Nov;42(11):1255-1266. doi: 10.1007/s40273-024-01414-7. Epub 2024 Aug 6.
2
Systematic Literature Review to Assess Economic Evaluations in Spinal Muscular Atrophy (SMA).脊髓性肌萎缩症(SMA)经济评估的系统文献回顾。
Pharmacoeconomics. 2022 Apr;40(Suppl 1):69-89. doi: 10.1007/s40273-021-01095-6. Epub 2021 Oct 18.
3
A Systematic Review of the Cost-Effectiveness of Biologics for Ulcerative Colitis.生物制剂治疗溃疡性结肠炎的成本效益的系统评价
Pharmacoeconomics. 2018 Apr;36(4):419-434. doi: 10.1007/s40273-017-0601-6.
4
Economic modelling of diagnostic and treatment pathways in National Institute for Health and Care Excellence clinical guidelines: the Modelling Algorithm Pathways in Guidelines (MAPGuide) project.经济建模在英国国家卫生与临床优化研究所临床指南中的诊断和治疗路径:指南中的建模算法路径(MAPGuide)项目。
Health Technol Assess. 2013 Dec;17(58):v-vi, 1-192. doi: 10.3310/hta17580.
5
The cost-effectiveness of domiciliary non-invasive ventilation in patients with end-stage chronic obstructive pulmonary disease: a systematic review and economic evaluation.终末期慢性阻塞性肺疾病患者家庭无创通气的成本效益:一项系统评价和经济学评估
Health Technol Assess. 2015 Oct;19(81):1-246. doi: 10.3310/hta19810.
6
Are adverse effects incorporated in economic models? An initial review of current practice.不良效应是否纳入经济模型?对当前实践的初步审查。
Health Technol Assess. 2009 Dec;13(62):1-71, 97-181, iii. doi: 10.3310/hta13620.
7
Digital interventions in mental health: evidence syntheses and economic modelling.数字干预在精神健康中的应用:证据综合和经济建模。
Health Technol Assess. 2022 Jan;26(1):1-182. doi: 10.3310/RCTI6942.
8
Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling.巴雷特食管的监测:通过系统评价、专家研讨会和经济模型探索不确定性
Health Technol Assess. 2006 Mar;10(8):1-142, iii-iv. doi: 10.3310/hta10080.
9
A cloud-based medical device for predicting cardiac risk in suspected coronary artery disease: a rapid review and conceptual economic model.一种基于云的医疗设备,用于预测疑似冠心病患者的心脏风险:快速审查和概念性经济模型。
Health Technol Assess. 2024 Jul;28(31):1-105. doi: 10.3310/WYGC4096.
10
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.

本文引用的文献

1
Infliximab versus ciclosporin in steroid resistant acute severe ulcerative colitis: a model-based cost-utility analysis of data from CONSTRUCT pragmatic trial.英夫利昔单抗与环孢素治疗激素耐药性急性重度溃疡性结肠炎:来自 CONSTRUCT 实用试验数据的基于模型的成本-效用分析。
BMC Health Serv Res. 2023 Mar 8;23(1):226. doi: 10.1186/s12913-023-09233-w.
2
PRISMA 2020 and PRISMA-S: common questions on tracking records and the flow diagram.PRISMA 2020 和 PRISMA-S:关于追踪记录和流程图的常见问题。
J Med Libr Assoc. 2022 Apr 1;110(2):253-257. doi: 10.5195/jmla.2022.1449.
3
Cost-effectiveness of tofacitinib compared with infliximab, adalimumab, golimumab, vedolizumab and ustekinumab for the treatment of moderate to severe ulcerative colitis in Germany.
托法替布与英夫利昔单抗、阿达木单抗、戈利木单抗、维得利珠单抗和乌司奴单抗治疗德国中重度溃疡性结肠炎的成本效果比较。
J Med Econ. 2021 Jan-Dec;24(1):279-290. doi: 10.1080/13696998.2021.1881323.
4
A Microsimulation Model to Project the 5-Year Impact of Using Hyperbaric Oxygen Therapy for Ulcerative Colitis Patients Hospitalized for Acute Flares.一种用于预测接受高压氧治疗的溃疡性结肠炎患者在急性发作期住院 5 年影响的微观模拟模型。
Dig Dis Sci. 2021 Nov;66(11):3740-3752. doi: 10.1007/s10620-020-06707-3. Epub 2020 Nov 13.
5
The association between disease activity and patient-reported outcomes in patients with moderate-to-severe ulcerative colitis in the United States and Europe.美国和欧洲中重度溃疡性结肠炎患者疾病活动度与患者报告结局的相关性。
BMC Gastroenterol. 2020 Jan 21;20(1):18. doi: 10.1186/s12876-020-1164-0.
6
Quality of life and patient preferences among Danish patients with ulcerative colitis - results from a survey study.丹麦溃疡性结肠炎患者的生活质量和患者偏好 - 一项调查研究的结果。
Curr Med Res Opin. 2020 May;36(5):771-779. doi: 10.1080/03007995.2020.1716704. Epub 2020 Jan 24.
7
Identification of the Most Cost-effective Position of Vedolizumab Among the Available Biologic Drugs for the Treatment of Ulcerative Colitis.识别维得利珠单抗在治疗溃疡性结肠炎的现有生物药物中的最具成本效益的位置。
J Crohns Colitis. 2020 Jun 19;14(5):575-587. doi: 10.1093/ecco-jcc/jjz212.
8
Cost-Effectiveness Analysis of Vedolizumab Compared with Other Biologics in Anti-TNF-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan.日本抗 TNF 初治中重度溃疡性结肠炎患者中维得利珠单抗与其他生物制剂的成本效果分析。
Pharmacoeconomics. 2020 Jan;38(1):69-84. doi: 10.1007/s40273-019-00841-1.
9
Identification, Review, and Use of Health State Utilities in Cost-Effectiveness Models: An ISPOR Good Practices for Outcomes Research Task Force Report.健康状态效用值在成本效果模型中的识别、评价和应用:ISPOR 疗效研究实践报告
Value Health. 2019 Mar;22(3):267-275. doi: 10.1016/j.jval.2019.01.004.
10
Budesonide with multi-matrix technology as second-line treatment for ulcerative colitis: evaluation of long-term cost-effectiveness in the Netherlands.具有多基质技术的布地奈德作为溃疡性结肠炎的二线治疗:荷兰长期成本效益评估
J Med Econ. 2018 Sep;21(9):869-877. doi: 10.1080/13696998.2018.1484371. Epub 2018 Jun 22.